Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination.
iScience
; 25(9): 104886, 2022 Sep 16.
Article
in English
| MEDLINE | ID: covidwho-1977403
ABSTRACT
The emergence of the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant has raised questions regarding resistance to neutralizing antibodies elicited by natural infection or immunization. We examined the neutralization activity of sera collected from previously SARS-CoV-2-infected individuals and SARS-CoV-2 naive individuals who received BBIBP-CorV or CoronaVac to BA.1 and the earlier variants Alpha, Beta, and Delta. Both sera from convalescent patients over three months after infection and two-dose BBIBP-CorV or CoronaVac vaccine recipients barely inhibited BA.1, less effectively neutralized Beta and Delta, and moderately neutralized Alpha. However, administering a single dose of BBIBP-CorV or CoronaVac in previously infected individuals or a third dose booster vaccination of BBIBP-CorV or CoronaVac in previously vaccinated individuals enhances neutralizing activity against BA.1 and other variants, albeit with a lower antibody titer for BA.1. Our data suggest that a booster vaccination is important to broaden neutralizing antibody responses against the variants.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Topics:
Vaccines
/
Variants
Language:
English
Journal:
IScience
Year:
2022
Document Type:
Article
Affiliation country:
J.ISCI.2022.104886
Similar
MEDLINE
...
LILACS
LIS